MGTX Stock — MeiraGTx Holdings PLC

MeiraGTx Holdings PLC (MGTX)

Updated October 16, 2026.

MGTX is a Stock. Total return is -38.1% over the past 8.4 years, 250.2 points behind SPY at 212.1%.

MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing treatments for serious diseases, including inherited retinal diseases, neurodegenerative conditions like Parkinson's disease and amyotrophic lateral sclerosis, and xerostomia, primarily using AAV gene therapy vectors. The company has multiple programs in clinical trials alongside preclinical-stage candidates, and maintains collaborations with Johnson & Johnson and Hologen Limited for research and commercialization. As a pre-revenue clinical-stage biotech company, it does not currently distribute to shareholders.

MGTX performance versus SPY

Price and return data through 2026-10-16.

Total return is -38.1% over the past 8.4 years, 250.2 points behind SPY at 212.1%. Over the past year its total return — price change plus distributions reinvested — is 14.2%. Its deepest 1-year drawdown was 38.0%.

MGTX key facts

Asset type

Stock

Asset class

Equity

Inception date

06/08/2018

Distribution frequency

None

Last close

$9.28 (as of 2026-10-16)

Market cap

$891,279,003

Average volume

666426.0

Beta

1.351

Payout ratio

0.0%

P/E ratio

10.67

Forward P/E

64.1026

EPS

$0.87

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MGTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 38.0%.

Who may consider MGTX — and who may not

It is a weaker fit for investors who need monthly cash flow (MGTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MGTX

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions